Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution
Article Sidebar
Main Article Content
Abstract
Ra-223 dichloride is a first-in-class alpha-emitting radiopharmaceutical recently introduced into clinical practice for treatment of men with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases. Due to the proven benefit on Overall Survival and the favorable toxicity profile, Ra-223 therapy is gaining widespread use in both US and Europe. In this article, we describe the routinary management of patients undergoing Ra-223 treatment in our Institution.
Currently, Ra-223 therapy is indicated for 6 intravenous injections (55 kBq per kg of body weight) administered every 28 days. In comparison to other radiopharmaceuticals, Ra-223 handling and administration do not need any additional training for authorized users. Due to the minimal external dose rate emission, Ra-223 dichloride can be delivered in an outpatient setting. Moreover, no particular precautions other than standard hygiene measures must be taken by patients’ family members or caregivers. Ra-223 therapy is associated to a favorable hematologic toxicity profile, while non-hematologic adverse events are generally mild and easy to manage.
Given the favorable toxicity profile of this treatment, clinical trials are currently ongoing to evaluate efficacy and safety of Ra-223 treatment in combination or sequence with recently approved drugs such as abiraterone acetate, enzalutamide and sipuleucel-T. In addition, the recent interest in Ra-223 bone lesion dosimetry could open the way to a dosimetric-based therapeutic approach with Ra-223. In this new scenario, results of these promising clinical trials may help clarifying the optimal sequencing of new therapeutic possibilities for metastatic CRPC and the appropriate eligibility criteria for Ra-223 treatment in oncologic patients.
Article Details
Copyright (c) 2017 Follacchio GA, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30. Ref.: https://goo.gl/Gu4WWo
Cookson MS, Roth BJ, Dahm P. Castration-resistant prostate cancer: AUA guideline. American Urological Association. 2014; Linthicum.
Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011; 14: 177-183. Ref.: https://goo.gl/ohSWGi
Yin L, Hu Q, Hartmann RW. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013; 14: 13958-13978. Ref.: https://goo.gl/cC6iiH
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369: 213-223. Ref.: https://goo.gl/uUS4uS
Bruland S, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra-223: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006; 12: 6250-6257. Ref.: https://goo.gl/ZSPNGN
Henriksen G, Breistol K, Bruland OS, Øystein Fodstad, Roy Larsen H. Significant antitumor effect from bone-seeking, alpha-particle-emitting Ra-223 demonstrated in an experimental skeletal metastases model. Cancer Res. 2002; 62: 3120-3125. Ref.: https://goo.gl/jhCGyY
Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with alpha-emitting Ra-223: comparison with the beta-emitter 89Sr in mice, J Nucl Med. 2003; 44: 252-259. Ref.: https://goo.gl/cST6kM
Li Y, Russell PJ, Allen BJ. Targeted alpha-therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther. 2004; 4: 459-68. Ref.: https://goo.gl/Mzhk5b
Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, et al. A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy. Phys Med Biol. 2012; 57: 3207-3222. Ref.: https://goo.gl/ZLdyMv
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005; 6: 392-400. Ref.: https://goo.gl/znMDH9
Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, et al. Systemic therapy in men with metastatic castration- resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014; 32: 3436-3448. Ref.: https://goo.gl/gmwgia
Cornford P, Bellmunt J, Bolla M, Erik Briers, Maria De Santis, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017; 71: 630-642. Ref.: https://goo.gl/cTDXQh
Cookson MS, Lowrance WT, Murad MH, Kibel AS, American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015; 193: 491-499. Ref.: https://goo.gl/zUWsFV
National Institute for Health and Care Excellence. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. Technology appraisal guidance TA412. 2016. Ref.: https://goo.gl/tLuJgf
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer version 2. 2017. Ref.: https://goo.gl/erMFCK
Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26: 69-77. Ref.: https://goo.gl/Vvdmvr
Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015; 9: 90-96. Ref.: https://goo.gl/K9JxGD
Bayer HealthCare Pharmaceuticals Inc; Xofigo (radium Ra 223 dichloride) injection, for intravenous use [package insert]. Wayne NJ: May 2013.
Vogelzang NJ, Fernandez DC, Morris MJ, Andrei Iagaru, Alan Brown et al. Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). J Clin Oncol. 2015; 33: 247. Ref.: https://goo.gl/YYMQZZ
Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of Ra-223-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013; 40: 1384-1393. Ref.: https://goo.gl/EqVKjT
Fayers PM, Aaronson NK, Bjordal K, et al. On behalf of EORTC Quality of Life Study Group. The EORTC QLQ-C30 Scoring manual(3rd edition). 2001, Brussels: EORTC.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991; 7: 6-9. Ref.: https://goo.gl/XLW39i
Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle S, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014; 15: 1397-1406. Ref.: https://goo.gl/bhy3tt
Zimmerman BE, Bergeron DE, Cessna JT, Fitzgerald R, Pibida L. Revision of the NIST Standard for Ra-223: New Measurements and Review of 2008 Data. J Res Natl Inst Stand Technol. 2015; 120: 37-57. Ref.: https://goo.gl/x8edF4
Bergeron DE, Cessna JT, Zimmerman BE. Secondary standards for Ra-223 revised. Appl Radiat Isot. 2015; 101: 10-14. Ref.: https://goo.gl/1MxwZe
Stabin MG, Siegel JA. Radiation Dose and Hazard Assessment of Potential Contamination Events during Use of Ra-223 Dichloride in Radionuclide Therapy. Health Phys. 2015; 109: 212-217. Ref.: https://goo.gl/hCFozK
Jensen M. Airborne Release Fraction Ra-223 dichloride. 2015, Report DTU-Hevesy Rad-150518.
Dauer LT, Williamson MJ, Humm J, O'Donoghue J, Ghani R, et al. Radiation safety considerations for the use of Ra-223 Cl2 in men with castration-resistant prostate cancer. Health Phys. 2014; 106: 494-504. Ref.: https://goo.gl/KxEui1
Smith DS, Stabin MG. Exposure Rate Constants and Lead Shielding Values for Over 1,100 Radionuclides. Health Phys. 2012; 102: 271-291. Ref.: https://goo.gl/iuJieq
McNamara MA, George DJ. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. BMC Cancer. 2015; 15: 371. Ref.: https://goo.gl/gPf3mi
De Vincentis G, Follacchio GA, Frantellizzi V, Liberatore M, Monteleone F, et al. Prostate-Specific Antigen flare phenomenon during 223Ra-dichloride treatment for bone metastatic Castration Resistant Prostate Cancer (mCRPC): a case report. Clin Genitourin Cancer. 2016; 14: 529-533. Ref.: https://goo.gl/pRqnkx
Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012; 30: 607-613. Ref.: https://goo.gl/3ZZYCW
Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001; 88: 226-230. Ref.: https://goo.gl/EeXa28
Parker C, O’Bryan-Tear CG, Bolstad B, Lokna A, Nilsson S. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. J Clin Oncol. 2011; 29: 49. Ref.: https://goo.gl/JbqTfm
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle S et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017; 28: 1090-1097. Ref.: https://goo.gl/53XkVq
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 61: 195-202. Ref.: https://goo.gl/yKBkCA
Michalski JM, Parker C, Sartor O, Vogelzang N, Haugen I, et al. Impact of prior docetaxel, extent of disease, and prior bisphosphonates on hematologic safety of radium-223 dichloride from ALSYMPCA. Int J Rad Oncol. 2014; 90: 441-442. Ref.: https://goo.gl/nkT1MC
Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, et al. Factors affecting Ra-223 therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016; 43: 8-20. Ref.: https://goo.gl/khmGAt
Logue J, Wedel S, Chodacki A, Sartor O, Nilsson S, et al. Reasons for patients (pts) discontinuing study treatment (tx) in the phase 3 ALSYMPCA trial of radium-223 dichloride (ra-223) in castration-resistant prostate cancer (CRPC) with bone metastases (mets). Ann Oncol. 2014; 25: 264-265. Ref.: https://goo.gl/cBYi2t
Bracarda S, Procopio G, Parker C, et al. Era 223-A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy naïve patients with bone-predominant metastatic Castration Resistant Prostate Cancer (Crpc). Ann Oncol. 2015; 26: 53-66.
University of Utah: Radium Ra 223 with Enzalutamide Compared to Enzalutamide Alone in Men with Metastatic Castration Refractory Prostate Cancer. [ClinicalTrials.gov identifier NCT02199197]. US National Institutes of Health, 2014, ClinicalTrials.gov (online). Accessed 26 Apr 2016. Ref.: https://goo.gl/VShJXe
Johns Hopkins University: A Phase 2 Study of Sipuleucel-T with or without Radium-223 in Men with Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer. [ClinicalTrials.gov identifier NCT02463799]. US National Institutes of Health, 2015, ClinicalTrials.gov (online). Accessed 26 Apr 2016. Ref.: https://goo.gl/kk3G3Z
Morris M, Higano C, Scher H, et al. Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: a phase 1/2a clinical trial. Ann Oncol. 2014; 25: 765.
Sartor AO, Amariglio R, Wilhelm S, Jose E Garcia-Vargas, C Gillies O'Bryan-Tear, et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol. 2013; 31: 5080. Ref.: https://goo.gl/DmsKFV
Sartor O, Heinrich D, Mariados N, María José Méndez-Vidal, Daniel Keizman, et al. Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC). J Clin Oncol. 2016; 34: 197. Ref.: https://goo.gl/aNUvKH
Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin cancer Res. 2005; 11: 4451-4459. Ref.: https://goo.gl/97uXmT
Bayer. Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone. [ClinicalTrials.gov identifier NCT02023697]. 2013. US National Institutes of Health, ClinicalTrials.gov (online). Accessed 26 Apr 2016. Ref.: https://goo.gl/TyaDM5
Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016; 43: 21-33. Ref.: https://goo.gl/VrMkBG
Coleman R, Huang L, Petrenciuc O, Paola Zaccarini. A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT)±radium-223 dichloride (Ra-223) in HER2 hormone receptor breast cancer patients (pts) with bone metastases (mets). J Clin Oncol. 2015; 33. Ref.: https://goo.gl/tuuVCJ
Gustave Roussy, Grand Paris. Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases from Differentiated Thyroid Cancer [ClinicalTrials.gov identifier NCT02390934]. US National Institutes of Health, 2014, ClinicalTrials.gov (online). 2016. Ref.: https://goo.gl/TT8Bik
Dana-Farber Cancer Institute: Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy In Patients With Metastatic Renal Cell Carcinoma and Bone Metastases [ClinicalTrials.gov identifier NCT02406521]. US National Institutes of Health, 2015, ClinicalTrials.gov (online). 2016. Ref.: https://goo.gl/AurwF9